{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:13:34Z","timestamp":1771564414601,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.mcna.2023.05.014","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T16:03:03Z","timestamp":1690905783000},"page":"27-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-syndromic and Syndromic Severe Acne in Adolescent Patients"],"prefix":"10.1016","volume":"108","author":[{"given":"Hsi","family":"Yen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Lalor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.mcna.2023.05.014_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjd.13462","article-title":"A\u00a0global perspective on the epidemiology of acne","volume":"172","author":"Tan","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2023.05.014_bib2","first-page":"13","article-title":"The epidemiology of acne vulgaris in late adolescence","volume":"7","author":"Lynn","year":"2016","journal-title":"Adolesc Health Med Ther"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjd.19477","article-title":"Reviewing the global burden of acne: how could we improve care to reduce the burden?","volume":"184","author":"Layton","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib4","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1038\/nrdp.2015.29","article-title":"Acne vulgaris","volume":"1","author":"Tuchayi","year":"2015","journal-title":"Nat Rev Dis Prim"},{"issue":"7","key":"10.1016\/j.mcna.2023.05.014_bib5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/ijd.15280","article-title":"The prevalence, risk factors, and psychosocial impacts of acne vulgaris in medical students: a literature review","volume":"60","author":"Sachdeva","year":"2021","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaad.2016.11.028","article-title":"Evidence-based recommendations for the management of acne fulminans and its variants","volume":"77","author":"Greywal","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2023.05.014_bib7","series-title":"Acne fulminans. StatPearls. Treasure Island, FL: StatPearls Publishing Copyright \u00a9 2022","author":"Zito","year":"2022"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib8","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1111\/pde.12983","article-title":"Acne Fulminans: Case Series and Review of the Literature","volume":"33","author":"Alakeel","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1468-3083.2010.03855.x","article-title":"Acne fulminans: explosive systemic form of acne","volume":"25","author":"Zaba","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2214\/ajr.162.5.8166004","article-title":"Bone disease in adolescents with acne fulminans and severe cystic acne: radiologic and scintigraphic findings","volume":"162","author":"Laasonen","year":"1994","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2133.1999.02982.x","article-title":"The treatment of acne fulminans: a review of 25 cases","volume":"141","author":"Seukeran","year":"1999","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2023.05.014_bib12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0190-9622(93)70076-6","article-title":"Acne fulminans: report of clinical findings and treatment of twenty-four patients","volume":"28","author":"Karvonen","year":"1993","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2230.1997.1830600.x","article-title":"Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone","volume":"22","author":"Tan","year":"1997","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000512032","article-title":"Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case","volume":"7","author":"Marasca","year":"2021","journal-title":"Skin Appendage Disord"},{"issue":"5 Suppl 1","key":"10.1016\/j.mcna.2023.05.014_bib15","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jaad.2004.09.006","article-title":"Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab","volume":"52","author":"Iqbal","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.mcna.2023.05.014_bib16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archdermatol.2012.855","article-title":"The Dark Side of Beauty: Acne Fulminans Induced by Anabolic Steroids in a Male Bodybuilder","volume":"148","author":"Kraus","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mcna.2023.05.014_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jdcr.2021.11.029","article-title":"Acne fulminans in a transgender boy after an increase in testosterone dosage","volume":"21","author":"Lee","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.clindermatol.2016.10.005","article-title":"Difficult and rare forms of acne","volume":"35","author":"Dessinioti","year":"2017","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.mcna.2023.05.014_bib19","series-title":"Acne conglobata. StatPearls. Treasure Island, FL: StatPearls Publishing Copyright \u00a9 2022","author":"Hafsi","year":"2022"},{"issue":"3","key":"10.1016\/j.mcna.2023.05.014_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2340\/00015555-1325","article-title":"Treatment of severe acne with low-dose isotretinoin","volume":"92","author":"Mehra","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"10.1016\/j.mcna.2023.05.014_bib21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2013.6678","article-title":"Adalimumab for the Treatment of Refractory Acne Conglobata","volume":"149","author":"Sand","year":"2013","journal-title":"JAMA Dermatology"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jaad.2005.06.008","article-title":"Treatment of acne conglobata with infliximab","volume":"55","author":"Shirakawa","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2023.05.014_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/ced.12540","article-title":"Acne conglobata and adalimumab: use of tumour necrosis factor-\u03b1 antagonists in treatment-resistant acne conglobata, and review of the literature","volume":"40","author":"Yiu","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0950-3579(94)80022-7","article-title":"The SAPHO syndrome","volume":"8","author":"Kahn","year":"1994","journal-title":"Bailliere\u2019s Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11832-014-0627-7","article-title":"SAPHO syndrome: A review","volume":"9","author":"Rukavina","year":"2015","journal-title":"Journal of Children's Orthopaedics"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.24540","article-title":"Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects","volume":"61","author":"Colina","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mcna.2023.05.014_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0049-0172(99)80027-4","article-title":"SAPHO syndrome: a long-term follow-up study of 120 cases","volume":"29","author":"Hayem","year":"1999","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.mcna.2023.05.014_bib28","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/rheumatology\/ken185","article-title":"Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome","volume":"47","author":"Hurtado-Nedelec","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.mcna.2023.05.014_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20912865","article-title":"Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update","volume":"12","author":"Liu","year":"2020","journal-title":"Therapeutic Advances in Musculoskeletal Disease"},{"issue":"3","key":"10.1016\/j.mcna.2023.05.014_bib30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semarthrit.2012.05.006","article-title":"The SAPHO Syndrome","volume":"42","author":"Nguyen","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib31","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/rheumatology\/kew015","article-title":"Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patients","volume":"55","author":"Li","year":"2016","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.mcna.2023.05.014_bib32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/jdv.18172","article-title":"Does SAPHO syndrome exist in dermatology?","volume":"36","author":"Chen","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib33","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjd.14691","article-title":"Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation","volume":"175","author":"Marzano","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semarthrit.2016.04.004","article-title":"SAPHO: Treatment options including bisphosphonates","volume":"46","author":"Zwaenepoel","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.24953\/turkjped.2017.02.011","article-title":"Successful treatment of a childhood synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with subcutaneous methotrexate: A case report","volume":"59","author":"Ak\u00e7aboy","year":"2017","journal-title":"Turk J Pediatr"},{"issue":"4","key":"10.1016\/j.mcna.2023.05.014_bib36","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.semarthrit.2018.04.003","article-title":"Biologics in SAPHO syndrome: A systematic review","volume":"48","author":"Daoussis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10067-018-4083-5","article-title":"Paradoxical skin lesions induced by anti-TNF-\u03b1 agents in SAPHO syndrome","volume":"38","author":"Li","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"25","key":"10.1016\/j.mcna.2023.05.014_bib38","doi-asserted-by":"crossref","first-page":"e11149","DOI":"10.1097\/MD.0000000000011149","article-title":"Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib","volume":"97","author":"Yang","year":"2018","journal-title":"Medicine (Baltim)"},{"issue":"4","key":"10.1016\/j.mcna.2023.05.014_bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-017-0265-1","article-title":"PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment","volume":"18","author":"Cugno","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1159\/000509874","article-title":"A\u00a0Unified Concept of Acne in the PAPA Spectrum Disorders","volume":"237","author":"Maitrepierre","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.mcna.2023.05.014_bib41","doi-asserted-by":"crossref","unstructured":"Holzinger D and Roth J. PAPA syndrome and the spectrum of PSTPIP1-associated inflammatory diseases, In: Efthimiou P., Auto-inflammatory syndromes: pathophysiology, diagnosis, and management, 2019, Springer International Publishing; Cham Switzerland, 39\u201359.","DOI":"10.1007\/978-3-319-96929-9_4"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.41976","article-title":"Excess Serum Interleukin-18 Distinguishes Patients With Pathogenic Mutations in PSTPIP1","volume":"74","author":"Stone","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00247-018-4246-1","article-title":"Imaging findings of sterile pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome: differential diagnosis and review of the literature","volume":"49","author":"Martinez-Rios","year":"2019","journal-title":"Pediatr Radiol"},{"issue":"3","key":"10.1016\/j.mcna.2023.05.014_bib44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum - a guide to diagnosis and management","volume":"19","author":"George","year":"2019","journal-title":"Clin Med"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/RHU.0b013e3181e969b9","article-title":"Clinical efficacy of etanercept for treatment of PAPA syndrome","volume":"16","author":"Tofteland","year":"2010","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.mcna.2023.05.014_bib46","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s10875-019-00685-6","article-title":"Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy","volume":"39","author":"Sood","year":"2019","journal-title":"J\u00a0Clin Immunol"},{"issue":"11","key":"10.1016\/j.mcna.2023.05.014_bib47","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/jdv.12765","article-title":"Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone","volume":"29","author":"Staub","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.mcna.2023.05.014_bib48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jvc2.52","article-title":"The efficacy of anti-IL-1 targeted therapy in PAPA and PASH syndrome","volume":"1","author":"Challamel","year":"2022","journal-title":"JEADV Clinical Practice"},{"issue":"3","key":"10.1016\/j.mcna.2023.05.014_bib49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/bjd.14383","article-title":"PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome","volume":"175","author":"Calder\u00f3n-Castrat","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib51","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jid.2016.02.801","article-title":"Whole Genome Linkage Analysis Followed by Whole Exome Sequencing Identifies Nicastrin (NCSTN) as a Causative Gene in a Multiplex Family with \u03b3-Secretase Spectrum of Autoinflammatory Skin Phenotypes","volume":"136","author":"Faraji Zonooz","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib52","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamadermatol.2013.2907","article-title":"Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene","volume":"149","author":"Marzano","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0019-5154.127667","article-title":"Profiling and hormonal therapy for acne in women","volume":"59","author":"Ghosh","year":"2014","journal-title":"Indian J Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment","volume":"14","author":"Escobar-Morreale","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib56","doi-asserted-by":"crossref","first-page":"847.e1-e10","DOI":"10.1016\/j.jaad.2014.05.007","article-title":"Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations","volume":"71","author":"Housman","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib57","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1542\/peds.2015-1430","article-title":"The Diagnosis of Polycystic Ovary Syndrome in Adolescents","volume":"136","author":"Rosenfield","year":"2015","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.mcna.2023.05.014_bib58","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaad.2015.05.026","article-title":"Evidence-based approach to cutaneous hyperandrogenism in women","volume":"73","author":"Schmidt","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib59","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40200-018-0371-5","article-title":"Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach","volume":"17","author":"Toosy","year":"2018","journal-title":"J\u00a0Diabetes Metab Disord"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib60","doi-asserted-by":"crossref","first-page":"859.e1-15","DOI":"10.1016\/j.jaad.2014.05.009","article-title":"Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment","volume":"71","author":"Buzney","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2023.05.014_bib61","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1100\/tsw.2004.106","article-title":"Clinical profiles, occurrence, and management of adolescent patients with HAIR-AN syndrome","volume":"4","author":"Omar","year":"2004","journal-title":"Sci World J"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0002-9378(83)90091-1","article-title":"Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features","volume":"147","author":"Barbieri","year":"1983","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.mcna.2023.05.014_bib63","first-page":"2385","article-title":"HAIR-AN syndrome: a multisystem challenge","volume":"63","author":"Elmer","year":"2001","journal-title":"Am Fam Physician"},{"issue":"4","key":"10.1016\/j.mcna.2023.05.014_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231749","article-title":"Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome","volume":"13","author":"O'Brien","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"5\u20136","key":"10.1016\/j.mcna.2023.05.014_bib65","first-page":"251","article-title":"The SAHA syndrome","volume":"54","author":"Orfanos","year":"2000","journal-title":"Horm Res"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib66","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaad.2013.09.014","article-title":"Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study","volume":"69","author":"Dalamaga","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.mcna.2023.05.014_bib67","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac003","article-title":"Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee","volume":"6","author":"Carmina","year":"2022","journal-title":"Journal of the Endocrine Society"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib68","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1468-3083.2010.03937.x","article-title":"Acne-associated syndromes: models for better understanding of acne pathogenesis","volume":"25","author":"Chen","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib69","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clindermatol.2016.10.007","article-title":"Drug-induced acne","volume":"35","author":"Kazandjieva","year":"2017","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40257-021-00665-w","article-title":"Treating Acne in Transgender Persons Receiving Testosterone: A Practical Guide","volume":"23","author":"Radi","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib71","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1559827616680593","article-title":"Performance-Enhancing Drug Use in Adolescence","volume":"11","author":"White","year":"2017","journal-title":"Am J Lifestyle Med"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5694\/j.1326-5377.2000.tb125667.x","article-title":"Anabolic-androgenic steroids: medical assessment of present, past and potential users","volume":"173","author":"O'Sullivan","year":"2000","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.mcna.2023.05.014_bib73","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1610-0387.2007.06176.x","article-title":"Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem","volume":"5","author":"Melnik","year":"2007","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"10","key":"10.1016\/j.mcna.2023.05.014_bib74","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.v16i1.361","article-title":"Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations","volume":"16","author":"Melosky","year":"2009","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.mcna.2023.05.014_bib76","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2023.05.014_bib77","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2023.05.014_bib78","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jcf.2022.09.002","article-title":"Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"21","author":"Hudson","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.mcna.2023.05.014_bib79","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamadermatol.2022.5208","article-title":"Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis","volume":"159","author":"Okroglic","year":"2023","journal-title":"JAMA Dermatol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712523000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712523000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:49:40Z","timestamp":1758419380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712523000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0025712523000743"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2023.05.014","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-syndromic and Syndromic Severe Acne in Adolescent Patients","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2023.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}